Near-Infrared Spectroscopy Measurements in Chronic Obstructive Pulmonary Disease

NCT ID: NCT06976762

Last Updated: 2025-05-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

140 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-05-01

Study Completion Date

2025-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Participants were selected based on three groups: healthy, chronic obstructive pulmonary disease, and chronic renal disease. NIRS was used to measure tissue oxygenation on the thenar region of the right hand. A pressure cuff was used to temporarily occlude arterial inflow, thus allowing the response to this to be assessed. The StO2 was plotted against time, and the following variables were calculated, the downslope, upslope, area under curve.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study was a prospective observational analysis involving patients with diagnosed Chronic Obstructive Pulmonary Disease (COPD) and Chronic Kidney Disease (CKD). Participants were recruited from the pulmonary and nephrology clinics at Gaziosmanpasa University Health Application and Research Centre during their stay in the ward. The study was approved by the Tokat Gaziosmanpasa Research Ethics Committee (Grant number: 20-KAEK-212) and all patients provided informed consent prior to participation.

Data collection involved baseline assessments of demographic characteristics, COPD severity, renal function, and comorbidities. Participants were divided into three groups: control, COPD, and CRD. Patients were visited during their stay in the ward and the measurement was initiated after five minutes of rest. Venous blood gas analysis was performed using the same sample of blood obtained for routine complete blood count analysis. A vascular occlusion test was conducted with NIRS measurements taken throughout. Three minutes of baseline measurement placing the probe on thenar eminence of the right hand was completed while the patient was lying with 45 degrees back up position. After baseline measurements a non-invasive blood pressure cuff was placed on the right arm and it was inflated to 250 mmHg. The cuff was held inflated for two minutes; after two minutes, the cuff was deflated and the measurement had been continued for another three minutes and stopped. Near-infrared spectroscopy measurements were obtained during and after vascular occlusion, including the area under curve (AUC) during occlusion (representing tissue hyperemia) and the angles of descent and ascent, which reflect muscle oxygen consumption and microcirculatory function, respectively.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Microcirculatory Status Spectroscopic Analysis COPD Renal Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

COPD

Patients with aged between 18 and 80 years, a confirmed diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, a post-bronchodilator forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) ratio of \<0.70, and clinically stable COPD, with no exacerbations or hospital admissions within the preceding four weeks were enrolled in this COPD group.

No interventions assigned to this group

CKD

Patients with aged between 18 and 80 years, evidence of CKD, an estimated glomerular filtration rate (eGFR) of \<60 mL/min/1.73 m² (Stages 3-5 CKD) on at least two occasions three months apart, or a history of renal replacement therapy were enrolled in CKD group.

No interventions assigned to this group

Control

Healthy individuals

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* To be eligible for the study, patients were required to meet all of the following criteria:

1. Age: Patients aged between 18 and 80 years.
2. COPD Diagnosis: A confirmed diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, including:

* A post-bronchodilator forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) ratio of \<0.70.
3. Renal Failure: Evidence of CKD, defined as:

* An estimated glomerular filtration rate (eGFR) of \<60 mL/min/1.73 m² (Stages 3-5 CKD) on at least two occasions three months apart, or a history of renal replacement therapy.
4. Stable Medical Condition: Clinically stable COPD, with no exacerbations or hospital admissions within the preceding four weeks.

Exclusion Criteria

* Patients were excluded from the study if they met any of the following criteria:

1. Acute Exacerbation: Evidence of an acute COPD exacerbation within four weeks prior to enrolment.
2. Other Respiratory Disorders: Coexistence of other chronic respiratory diseases such as asthma, interstitial lung disease, or bronchiectasis that might interfere with the assessment of COPD.
3. Renal Transplantation: History of kidney transplantation, as immunosuppressive therapy may affect disease progression and outcomes.
4. Uncontrolled Comorbidities: Presence of any uncontrolled comorbid conditions, including:

* Cardiovascular instability or recent myocardial infarction (within six months).
* Active malignancy (other than localized skin cancer).
* Severe liver disease (e.g., cirrhosis with hepatic failure).
5. Pregnancy or Breastfeeding: Women who were pregnant or breastfeeding at the time of study enrolment.
6. Cognitive Impairment: Any condition that would impair the ability to provide informed consent or participate in study procedures, such as dementia or significant psychiatric disorders.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tokat Gaziosmanpasa University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Serkan Dogru

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Daniel MARTIN, Professor

Role: PRINCIPAL_INVESTIGATOR

Uni of Plymouth, Dept of Periop and ICU, Plymouth, UK

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tokat Gaziosmanpasa University

Tokat Province, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20-KAEK-212

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.